Organic Chemistry and Biochemistry Institute in Prague. The research group, led by Pavel Mayer, developed a compound that can receive focal alopecia treatment, an autoimmune disease that causes hair loss and bald spot. The results of the study recently published in the Medical Journal of Medicine confirmed the effectiveness of the drug based on itacononic acid derivatives known as itaconrates. Published in İş Magazine Journal of Medical Chemistry (JMC).
Focal alopecia is an autoimmune disease in which the immune system attacks hair follicles, inflammation and consequently violates hair loss and growth. This affects approximately 2% of the population, especially women and the second most common cause of hair loss after androgenetic alopecia (male baldness).
To date, alopecia treatment is mainly based on the use of corticosteroids, which often cause serious side effects.
Itacoic acid is a natural substance with significant anti -inflammatory properties caused by interaction with the immune system. However, ordinary itaconat weakly penetrates the cells that limit its efficiency. The Pavel Mayer team, who has developed a drug for alopecia for several years, solved this problem, creating compounds that only turned into an active substance in the body.
“We have developed a series of production with at least two high efficiency. The mouse tests confirmed that the compounds were well absorbed and the active substance in the skin was released at the desired concentration. Our ITaconata derivatives can become a completely new method for the treatment of alopecia. ”
In particular, the new remedy, probably, is probably not only applied in the form of ointment, it can be taken orally in the form of tablets. Opening expectations were appreciated by the pharmaceutical company SPARC, a pharmaceutical company, which is licensed to use patented technology based on ITACO acid elements.
SCD-153, one of the advanced compounds, reduces inflammation when applied in the form of an ointment, protects hair follicles and accelerates the growth of new hair according to the results of the previous tests on mice. It contributes to the active state of follicles from sleep. SPARC has started a number of patients for the first stage of clinical tests of this promising drug.
Previously named The age in which mental abilities reach the peak.
What are you thinking?
Source: Gazeta
Barbara Dickson is a seasoned writer for “Social Bites”. She keeps readers informed on the latest news and trends, providing in-depth coverage and analysis on a variety of topics.